1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1185/030079902125001353" target="_blank" rel="noreferrer">http://doi.org/10.1185/030079902125001353</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Focus on paroxetine
Publisher
An entity responsible for making the resource available
Current Medical Research And Opinion
Date
A point or period of time associated with an event in the lifecycle of the resource
2003
Subject
The topic of the resource
Humans; Treatment Outcome; Drug Interactions; Animals; Antidepressive Agents; Stress Disorders; Anxiety Disorders/drug therapy; Depression/drug therapy; Paroxetine/administration & dosage/adverse effects/pharmacokinetics/therapeutic use; Post-Traumatic/drug therapy; Second-Generation/administration & dosage/adverse effects/pharmacokinetics/therapeutic use; Serotonin Uptake Inhibitors/administration & dosage/adverse effects/pharmacokinetics/therapeutic use; Substance Withdrawal Syndrome
Creator
An entity primarily responsible for making the resource
Green B
Description
An account of the resource
This review of paroxetine is based on Medline and PsycLit searches and a manual search of the available research literature. It aims to cover the pharmacology of this frequently prescribed SSRI antidepressant in terms of its indications, efficacy and adverse effects. Overall, paroxetine is a well-tolerated and safe first-line SSRI antidepressant with anxiolytic qualities. It has been found useful in depression, anxiety and other conditions such as obsessive compulsive disorder and post-traumatic stress disorder. The antidepressant has some advantages over earlier tricyclic medication in terms of a lack of cardiovascular side-effects and relative safety in overdose. Cessation of use, however, is associated with withdrawal or discontinuation symptoms and patients should be counselled as to how these might be avoided. A 3- or 4-week graded withdrawal regimen, perhaps with concomitant fluoxetine to cover serotonergic discontinuation symptoms, may be advisable.
2003
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1185/030079902125001353" target="_blank" rel="noreferrer">10.1185/030079902125001353</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
2003
Animals
Antidepressive Agents
Anxiety Disorders/drug therapy
Backlog
Current Medical Research And Opinion
Depression/drug therapy
Drug Interactions
Green B
Humans
Journal Article
Paroxetine/administration & dosage/adverse effects/pharmacokinetics/therapeutic use
Post-Traumatic/drug therapy
Second-Generation/administration & dosage/adverse effects/pharmacokinetics/therapeutic use
Serotonin Uptake Inhibitors/administration & dosage/adverse effects/pharmacokinetics/therapeutic use
Stress Disorders
Substance Withdrawal Syndrome
Treatment Outcome